Article
Genetic Investigation of Corrected QT Interval Sensitivity to Oral Bepridil Hydrochloride Hydrate in Patients With Atrial Fibrillation.
Journal of the American Heart Association - 16 Jun 2026
Ishibashi Naoki, Furutani Motoki, Nakashima Mika, Ishida Shunsuke, Maeda Junji, Sakai Takumi, Oguri Naoto, Miyamoto Shogo, Miyauchi Shunsuke, Okamura Sho, Okubo Yousaku, Tokuyama Takehito, Oda Noboru, Nishiki Takumi, Mitsumori Risa, Niida Shumpei, Ozaki Kouichi, Shigemizu Daichi, Itoh Hideki, Nakano Yukiko
Abstract excerpt
BACKGROUND: Bepridil is an antiarrhythmic drug used to treat paroxysmal atrial fibrillation; however, its use is limited by corrected QT interval (QTc) prolongation and the risk of ventricular arrhythmias. This study aimed to identify genetic variants associated with bepridil-associated QTc prolongation after catheter ablation for paroxysmal atrial fibrillation. METHODS: A total of 523 patients who initiated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
